Zika Virus Purified Inactivated Vaccine (ZPIV)

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Zika Virus Infection

Phase 1

ZIKA Vaccine in Naive Subjects

CompletedNCT02952833

National Institute of Allergy and Infectious Diseases (NIAID)Zika Virus Infection

Start: 2016-10-14End: 2018-12-05Updated: 2025-07-29

A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.

CompletedNCT02963909

National Institute of Allergy and Infectious Diseases (NIAID)Zika Virus Infection

Start: 2016-11-01End: 2018-10-30Updated: 2024-04-22

Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area

CompletedNCT03008122

National Institute of Allergy and Infectious Diseases (NIAID)Zika Virus Infection

Start: 2017-03-21End: 2021-08-10Updated: 2023-04-06

Related Papers

Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.

2023-06-2715 citations

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.

2017-12-05230 citations

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.

2017-12-05156 citations